TriangleBiopsy Procedure (NCT06039371)
Biopsy Procedure trial for Castration-Resistant Prostate Carcinoma (NCT06039371). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic castration-resistant prostate cancer progressing after an androgen-receptor-signaling inhibitor, without prior chemotherapy for castration-resistant disease or cancer-related pain. The radiotherapy cohort requires PSMA-positive imaging.
The idea: high-dose testosterone may damage DNA in hormone-resistant tumor cells. Patients continue androgen deprivation and choose testosterone with carboplatin, etoposide, or PSMA-targeted lutetium radiation. Subgroups differ in which treatment starts first. Biopsies and scans assess effects; researchers measure PSA response.
This phase 2 study plans 69 patients. Michael Schweizer leads at Fred Hutch/University of Washington, Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.